Cancer clinical trials in the region Pays de la Loire

433 currently recruiting clinical trials
Region Pays de la Loire
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b extension de dose et phase 2 cohortes tumeurs solides naïves d'inhibiteurs de KRAS G12C
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Targeted therapy
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06128551
Phase 1b Escalade de dose
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Revolution Medicines, Inc.
Phase 1 / Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT04585750 #2023-504251-27-00
Phase 2 autres tumeurs solides
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Lung cancer #NCT06772623 #2024-514465-18-00
Partie 2 (Optimisation de la dose)
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK BRAF EGFR HER2 HRAS KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
7 recruiting sites
Abbvie
Phase 1 / Phase 2 Breast cancer #NCT06827236 #2024-517979-20-00
Partie 1
Required HER2 statuses
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
BioNTech SE
Phase 1 / Phase 2 Acute leukemia #NCT04988555 #2022-502741-10-00
Phase 1, bras A, B, E et F
Required histologic types
Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Other acute leukemia
Required central nervous system lesions
None Treated / Controled
Required renal function statuses
> 60 ml/min 50-60 ml/min
Required genetic anomalies
KMT2A MLL fusions NPM1
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
8 recruiting sites
Sumitomo Pharma America, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05181735 #2021-000596-37
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo Secondary MDS
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
EPO / Growth factors
Required IPSS-R prognostic scores
Low Intermediate
Required IPSS-M prognostic scores
Low Moderately low
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Systemic Treatment-Naive
27 recruiting sites
Groupe Francophone des Myélodysplasies
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05280509
Phase 2 Cohorte 2 (réponse sous-optimale au ruxolitinib)
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
1
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT05280509
Phase 2 Cohorte 1 Myélofibrose naïve au traitement par JAKi
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Excluded previous treatments
Targeted therapy
5 recruiting sites
Telios Pharma, Inc.
Phase 1 / Phase 2 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT04176198 #2022-502597-16-00
Bras Nuvisertib (TP-3654) + Ruxolitinib
Required histologic types
Myeloproliferative neoplasms (MPN)
Required histologic sub types
Primary myelofibrosis Secondary myelofibrosis
Required number of previous lines of therapy
None
Required previous treatments
Targeted therapy
Required DIPSS scores
Intermediate-1 Intermediate-2 High
Required M-IPSS70+ v2.0 scores
Intermediate High
Required MYSEC-PM scores
Intermediate-1 Intermediate-2 High
8 recruiting sites
Sumitomo Pharma America, Inc.